{"pmid":32313885,"pmcid":"PMC7164888","title":"COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.","text":["COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.","The COVID-19 pandemic has resulted in a proliferation of clinical trials that are designed to slow the spread of SARS-CoV-2, the virus that causes COVID-19. The overwhelming majority of cardiovascular and cancer patients are at increased risk for SARS-CoV-2 infection; accordingly, the cardiovascular and cardio-oncology communities are playing a major role in caring for COVID-19 patients. Many of the therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, drugs that were not effective in Ebola patients, or treatments for malaria that were developed decades ago, and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here we have provided a foundation for cardiovascular and cardio-oncology physicians who are on the frontline providing care to COVID-19 patients, so that they can better understand the emerging cardiovascular epidemiology of COVID-19, as well as the biological rationale for the clinical trials that are ongoing for the treatment of COVID-19 patients.","JACC CardioOncol","Ky, Bonnie","Mann, Douglas L","32313885"],"abstract":["The COVID-19 pandemic has resulted in a proliferation of clinical trials that are designed to slow the spread of SARS-CoV-2, the virus that causes COVID-19. The overwhelming majority of cardiovascular and cancer patients are at increased risk for SARS-CoV-2 infection; accordingly, the cardiovascular and cardio-oncology communities are playing a major role in caring for COVID-19 patients. Many of the therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, drugs that were not effective in Ebola patients, or treatments for malaria that were developed decades ago, and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here we have provided a foundation for cardiovascular and cardio-oncology physicians who are on the frontline providing care to COVID-19 patients, so that they can better understand the emerging cardiovascular epidemiology of COVID-19, as well as the biological rationale for the clinical trials that are ongoing for the treatment of COVID-19 patients."],"journal":"JACC CardioOncol","authors":["Ky, Bonnie","Mann, Douglas L"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32313885","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jaccao.2020.04.002","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664714520027725824,"score":8.518259,"similar":[{"pmid":32309679,"pmcid":"PMC7162643","title":"COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.","text":["COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities.","The COVID-19 pandemic has resulted in a proliferation of clinical trials that are designed to slow the spread of SARS-CoV-2, the virus that causes COVID-19. The overwhelming majority of cardiovascular and cancer patients are at increased risk for SARS-CoV-2 infection; accordingly, the cardiovascular and cardio-oncology communities are playing a major role in caring for COVID-19 patients. Many of the therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, drugs that were not effective in Ebola patients, or treatments for malaria that were developed decades ago, and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here we have provided a foundation for cardiovascular and cardio-oncology physicians who are on the frontline providing care to COVID-19 patients, so that they can better understand the emerging cardiovascular epidemiology of COVID-19, as well as the biological rationale for the clinical trials that are ongoing for the treatment of COVID-19 patients.","JACC Basic Transl Sci","Ky, Bonnie","Mann, Douglas L","32309679"],"abstract":["The COVID-19 pandemic has resulted in a proliferation of clinical trials that are designed to slow the spread of SARS-CoV-2, the virus that causes COVID-19. The overwhelming majority of cardiovascular and cancer patients are at increased risk for SARS-CoV-2 infection; accordingly, the cardiovascular and cardio-oncology communities are playing a major role in caring for COVID-19 patients. Many of the therapeutic agents that are being used to treat patients with COVID-19 are repurposed treatments for influenza, drugs that were not effective in Ebola patients, or treatments for malaria that were developed decades ago, and are unlikely to be familiar to the cardiovascular and cardio-oncology communities. Here we have provided a foundation for cardiovascular and cardio-oncology physicians who are on the frontline providing care to COVID-19 patients, so that they can better understand the emerging cardiovascular epidemiology of COVID-19, as well as the biological rationale for the clinical trials that are ongoing for the treatment of COVID-19 patients."],"journal":"JACC Basic Transl Sci","authors":["Ky, Bonnie","Mann, Douglas L"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32309679","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.jacbts.2020.04.003","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664632501377695744,"score":1396.3821},{"pmid":32282502,"title":"Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).","text":["Cardiovascular Considerations in Treating Patients with Coronavirus (COVID-19).","A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions.","J Cardiovasc Pharmacol","Dixon, Dave L","Van Tassell, Benjamin W","Vecchie, Alessandra","Bonaventura, Aldo","Talasaz, Azita","Kakavand, Hesam","D'Ascenzo, Fabrizio","Perciaccante, Antonio","Castagno, Davide","Ammirati, Enrico","Biondi-Zoccai, Giuseppe","Stevens, Michael","Abbate, Antonio","32282502"],"abstract":["A novel betacoronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread rapidly across the globe since December 2019. Coronavirus disease 2019 (COVID-19) has a significantly higher mortality rate than seasonal influenza and has disproportionately affected older adults, especially those with cardiovascular disease and related risk factors. Adverse cardiovascular sequalae, such has myocarditis, acute myocardial infarction, and heart failure, have been reported in patients with COVID-19. No established treatment is currently available; however, several therapies, including remdesivir, hydroxychloroquine and chloroquine, and interleukin (IL)-6 inhibitors, are being used off-label and evaluated in ongoing clinical trials. Considering these therapies are not familiar to cardiovascular clinicians managing these patients, this review describes the pharmacology of these therapies in the context of their use in patients with cardiovascular-related conditions."],"journal":"J Cardiovasc Pharmacol","authors":["Dixon, Dave L","Van Tassell, Benjamin W","Vecchie, Alessandra","Bonaventura, Aldo","Talasaz, Azita","Kakavand, Hesam","D'Ascenzo, Fabrizio","Perciaccante, Antonio","Castagno, Davide","Ammirati, Enrico","Biondi-Zoccai, Giuseppe","Stevens, Michael","Abbate, Antonio"],"date":"2020-04-14T11:00:00Z","year":2020,"_id":"32282502","week":"202016|Apr 13 - Apr 19","doi":"10.1097/FJC.0000000000000836","source":"PubMed","topics":["Treatment"],"weight":1,"e_drugs":["remdesivir","Chloroquine","Hydroxychloroquine"],"_version_":1664636703940280320,"score":305.77032},{"pmid":32317203,"title":"Cardiovascular complications in COVID-19.","text":["Cardiovascular complications in COVID-19.","BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19.","Am J Emerg Med","Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael","32317203"],"abstract":["BACKGROUND: The coronavirus disease of 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). While systemic inflammation and pulmonary complications can result in significant morbidity and mortality, cardiovascular complications may also occur. OBJECTIVE: This brief report evaluates cardiovascular complications in the setting of COVID-19 infection. DISCUSSION: The current COVID-19 pandemic has resulted in over one million infected worldwide and thousands of death. The virus binds and enters through angiotensin-converting enzyme 2 (ACE2). COVID-19 can result in systemic inflammation, multiorgan dysfunction, and critical illness. The cardiovascular system is also affected, with complications including myocardial injury, myocarditis, acute myocardial infarction, heart failure, dysrhythmias, and venous thromboembolic events. Current therapies for COVID-19 may interact with cardiovascular medications. CONCLUSIONS: Emergency clinicians should be aware of these cardiovascular complications when evaluating and managing the patient with COVID-19."],"journal":"Am J Emerg Med","authors":["Long, Brit","Brady, William J","Koyfman, Alex","Gottlieb, Michael"],"date":"2020-04-23T11:00:00Z","year":2020,"_id":"32317203","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ajem.2020.04.048","keywords":["acute myocardial infarction","covid-19","cardiovascular","dysrhythmia","heart failure","infectious disease","myocarditis","troponin"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664815087672623104,"score":226.49368},{"pmid":32301766,"title":"Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.","text":["Cardiovascular Pharmacology in the Time of COVID-19: A Focus on Angiotensin Converting Enzyme 2.","Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy.","J Cardiovasc Pharmacol","Buckley, Leo F","Cheng, Judy W M","Desai, Akshay","32301766"],"abstract":["Coronavirus disease-2019 (COVID-19) has emerged as a pandemic affecting millions of adults. Severe acute respiratory syndrome coronavirus-2019 (SARS-CoV-2), the causative virus of COVID-19, infects host cells through angiotensin converting enzyme 2 (ACE2). Pre-clinical models suggest that ACE2 upregulation confers protective effects in acute lung injury. Additionally, renin-angiotensin aldosterone system inhibitors reduce adverse atherosclerotic cardiovascular disease, heart failure and chronic kidney disease outcomes, but may increase ACE2 levels. We review current knowledge of the role of ACE2 in cardiovascular physiology and SARS-CoV-2 virology as well as clinical data to inform the management of patients with or at risk for COVID-19 who require renin-angiotensin-aldosterone system inhibitor therapy."],"journal":"J Cardiovasc Pharmacol","authors":["Buckley, Leo F","Cheng, Judy W M","Desai, Akshay"],"date":"2020-04-18T11:00:00Z","year":2020,"_id":"32301766","week":"202016|Apr 13 - Apr 19","doi":"10.1097/FJC.0000000000000840","source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"e_drugs":["Aldosterone"],"_version_":1664635401196797953,"score":223.78185},{"pmid":32286678,"title":"Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","text":["Inhibitors of the renin-angiotensin system: The potential role in the pathogenesis of COVID-19.","Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians.","Cardiol J","Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng","32286678"],"abstract":["Coronavirus disease 2019 (COVID-19), which initially began in China, has spread to other countries of Asia, Europe, America, Africa and Oceania, with the number of confirmed cases and suspected cases increasing each day. According to recently published research, it was found that the majority of the severe cases were elderly, and many of them had at least one chronic disease, especially cardiovascular diseases. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEIs/ARBs) are the most widely used drugs for cardiovascular diseases. The clinical effect of ACEIs/ARBs on patients with COVID-19 is still uncertain. This paper describes their potential role in the pathogenesis of COVID-19, which may provide useful in the advice of cardiologists and physicians."],"journal":"Cardiol J","authors":["Huang, Ziyin","Jiang, Yufeng","Chen, Jingjing","Zhou, Yafeng"],"date":"2020-04-15T11:00:00Z","year":2020,"_id":"32286678","week":"202016|Apr 13 - Apr 19","doi":"10.5603/CJ.a2020.0056","keywords":["2019-ncov","covid-19","angiotensin-converting enzyme inhibitors","renin-angiotensin system"],"source":"PubMed","topics":["Treatment","Mechanism"],"weight":1,"locations":["China","America"],"countries":["China"],"countries_codes":["CHN|China"],"_version_":1664636391618772992,"score":218.54181}]}